Nanjing Bode Biopharmaceutical

Nanjing Bode Biopharmaceutical is a clinical-stage biotechnology company based in Nanjing, China, specializing in the development of innovative peptide therapeutics for metabolic and cardiovascular diseases. The company leverages its proprietary long-acting peptide technology and oral delivery platforms to create next-generation treatments for conditions such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Its lead candidates include multi-receptor agonists targeting GLP-1, GIP, and Glucagon pathways, designed to provide superior efficacy and patient convenience. Nanjing Bode is backed by prominent venture capital firms and maintains a robust pipeline of metabolic-focused programs. The company aims to address significant unmet medical needs in the global metabolic disease market through its advanced molecular engineering capabilities.